Scalper1 News
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half of overall revenue. Reporting before the open, Regeneron logged fourth-quarter revenue of $802.3 million, up 31% from the prior year and above consensus analyst views of $781.5 million. On the Scalper1 News
Scalper1 News